Role of Deferoxamine in Tumor Therapy

Acta Haematologica

Volumn 95, Issue 1, 1996, Pages 66-69

  Donfrancesco, A ^a   Deb, G ^a   De Sio, L ^a   Cozza, R ^a   Castellano, A ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Deferoxamine; Iron; Neuroblastoma; Tumor therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CHELATING AGENT; DEFEROXAMINE; FERRITIN; IRON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; LUNG DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROBLASTOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; DEFEROXAMINE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; NEOPLASMS; NEUROBLASTOMA;

EID: 0030031404     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203951     Document Type: Article

References (16)

1. Stevens RG: Iron and the risk of cancer. Med Oncol Tumor Pharmacother 1990;7:177-181.
2. Keberle H: The biochemistry of deferoxamine and its relation to iron metabolism. Ann NY Acad Sci 1964;119:758-768.
3. Pinkerton CR, Hartman O, Dini G, Philip T: High dose chcmoradiotherapy with bone marrow rescue in stage IV neuroblastoma: EBMT Survey 1988; in Dicke KA. Spitzer G, Jagan-nath S, Evinger-Hodges MJ (eds): Autologous Bone Marrow Transplantation. Houston, University of Texas MD Anderson Canccr Center, 1989, pp 344-348.
4. Reynolds CP. Moss TJ, Feig SA, Selch M, Mat-thay KK, Wells J, Seeger RC: Treatment of poor prognostic neuroblastoma with intensive therapy and autologous bone marrow transplantation; in Dicke K.A, Spitzer G, Jagannath S, Evinger-Hodges MJ (eds): Autologous Bone Marrow' Transplantation. Houston. University of Texas MD Anderson Canccr Center, 1989, pp 575-583.
5. Iancu TC, Shiloh H, Kedar A: Neuroblastoma contain iron-rich ferritin. Cancer 1988;61: 2497-2502.
6. Blatt J, Stitely S: Antineuroblastoma activity of deferoxamine in human cell lines. Cancer Res 1987;47:1749-1750.
7. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello M, Helson L: Effects of a single course of deferoxamine in neuroblastoma patients. Canccr Res 1990;50:4929-4930.
8. Hann HW, Stahltut MW, Rubin R, Maddrey WC: Antitumor cffcct of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice. Cancer 1992;70:2051— 2056.
9. Seligman PA, Schleicher RB. Siriwardana G, Domenico J, Gelfand EW: Effects of agents that inhibit ccllular iron incorporation on bladder cancer cell proliferation. Blood 1993:82: 1608-1617.
10. Estrov Z, Tawa A, Wang XH, Dube ID, Sulh H, Cohen A, Gelfand EW: In vitro and in vivo effects of deferoxamine in neonatal acute leukemia. Blood 1987;69:757-761.
11. Kaplinsky C, Schvartzmayer S, Goshen Y: Desferal treatment in 3 leukemic patients (abstract). SlOP Meeting, Trondheim, 1988.
12. Skala JP, Rogers PC, Chan KW, Chao HY, Rodriguez WC: Deferoxamine as a purging agent for autologous bone marrow grafts in neuroblastoma. Prog Clin Biol Res 1992,377: 71-78.
13. Richardson D, Ponka P, Baker E: The effect of the iron (III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res 1994;54:685-689.
14. Frantz CN, Bernstein M, Castelberry R, Vietti T: Dose escalation of desferrioxamine (DFO) in children with refractory neuroblastoma: A pediatric Oncology Group study (abstract 1420). Proceedings Am Soc Clin Oncol 1994, 416.
15. Donfrancesco A, Deb G, Dominici C, Angioni A, Caniglia M, De Sio L, Fidani P, Amici A, Helson L: Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotcpa (D-CE-CaT): A new cytoreductive chelation-chcmo-thcrapy regimen in patients with advanced neuroblastoma. Am J Clin Oncol 1992; 15:319— 322.
16. Donfrancesco A, De Bernardi B, Carli M, Mancini A, Nigro M, De Sio L, Casale F, Bagnulo S, Helson L, Deb G, for the Italian Neuroblastoma Cooperative Group: Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma: Preliminary results. Eur J Cancer, 1995;31 A:612-615.